DNA topoisomerase IIα (TOP2A) plays a vital role in replication and cell division by catalytically altering DNA topology. It is a prominent target for anticancer drugs. However, it is currently unknown whether TOP2A is O-GlcNAc-modified, and the mechanism by which interplay between TOP2A and O-GlcNAcylation affects breast cancer chemotherapeutic drug resistance remains unclear.